Bednarska Sylwia, Siejka Agnieszka
Department of Clinical Endocrinology, Medical University of Lodz, Łódź, Poland.
Adv Clin Exp Med. 2017 Mar-Apr;26(2):359-367. doi: 10.17219/acem/59380.
Polycystic ovary syndrome (PCOS) is currently the leading cause of menstrual complications in women. It is characterized by clinical and/or biochemical hyperandrogenism, ovulation abnormalities and the presence of enlarged and/or polycystic ovaries in ultrasound images (12 or more small bubbles located circumferentially and/or ovarian volume > 10 mL). It is often comorbid with hyperinsulinemia, dyslipidemia, overweight or obesity, and is a risk factor for the development of diabetes and cardiovascular diseases (CVDs). The treatment of patients with PCOS depends on the prevailing symptoms. The aim of this paper is to present the etiopathogenesis, clinical and biochemical implications, and non-pharmacological and pharmacological treatment options - those approved by worldwide scientific organizations as well as new therapies whose initial results are encouraging enough to prompt researchers to explore them further.
多囊卵巢综合征（PCOS）是目前女性月经紊乱的主要原因。其特征为临床和/或生化高雄激素血症、排卵异常以及超声图像显示卵巢增大和/或多囊样改变（12个或更多小卵泡沿周边排列和/或卵巢体积>10 mL）。它常与高胰岛素血症、血脂异常、超重或肥胖并存，是糖尿病和心血管疾病（CVDs）发生的危险因素。PCOS患者的治疗取决于主要症状。本文旨在介绍其发病机制、临床和生化影响以及非药物和药物治疗选择——那些已获全球科学组织批准的治疗方法以及初步结果令人鼓舞、促使研究人员进一步探索的新疗法。
